prexasertib
ACR-368 Small Molecule Target: CHK1, CHK2
Acrivon Therapeutics
Most recent annual filing: 2026-03-15
Pipeline (5 active programs)
ACR-2316
Small Molecule Target: WEE1, PKMYT1
ACR-6840
Small Molecule Target: CDK11
ACR-368
Small Molecule Target: CHK1, CHK2
Technology platforms
AP3
Generative Phosphoproteomics Acrivon Predictive Precision Proteomics platform — quantifies compound-specific, drug-regulated pathway activity levels inside the intact cell via MS-based proteomic profiling and automated tumor imaging biomarker platform; applied to oncology drug discovery, patient selection (OncoSignature tests), indication finding, and resistance mechanism identification
Biotech Distilled coverage (11)
- 2026-05-13 UPDATE: Acrivon (ACRV) - The 2H 2026 Catalyst Just Got Locked In 🔒 Paid
- 2026-04-27 UPDATE: Acrivon (ACRV) - RA Capital Just Backstopped the ATM at $1.80 🔒 Paid
- 2026-03-21 UPDATE: Acrivon (ACRV) - The Partnership Pitch Takes Shape Ahead of AACR 🔒 Paid
- 2026-03-07 UPDATE: Acrivon (ACRV) - Officially Cuts the Cord with its Diagnostic Vendor 🔒 Paid
- 2026-02-28 UPDATE: Acrivon (ACRV) - The Late-Breaking Letdown and the Anatomy of a Friday Flush. 🔒 Paid
- 2026-02-21 UPDATE: Acrivon (ACRV) Brings Its Moat In-House. 🔒 Paid
- 2026-01-25 Update: Acrivon (ACRV) - Catalyst Added: ACRV Takes the Main Stage in Europe. 🔒 Paid
- 2026-01-17 Insider Alert: Acrivon (ACRV) - Executives Are Eating Their Own Cooking.
- 2026-01-10 UPDATE: Acrivon (ACRV) Granular Review: Did the Market Just Throw the Baby Out with the Bathwater? 🔒 Paid
- 2026-01-08 ACRV UPDATE: Platform Supported. Acrivon (ACRV) Clears the Bar.
- 2026-01-05 Acrivon Therapeutics (ACRV): Scientific Deep Dive for ACR-2316 and ACR-368 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.